Health Care/Hospital Global News & Press Release Distribution

Lerna Bio unveils its first-in-class solution to combat liver failure

SINGAPORE, CAMBRIDGE, Mass. and SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Lerna Biopharma Pte. Ltd (Lerna Bio) proudly announces the unveiling of its pioneering liver regeneration drug candidate, LR1, at The Liver Meeting inBoston organized by American Association for the Study of Liver Diseases (AA...

2023-11-06 22:00 1254

I-Mab Announces Participation at Jefferies and Piper Conferences in November

ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies...

2023-11-06 21:00 1092

Lunit to Present Seven AI-Powered Radiology Studies at RSNA 2023

* Two oral presentations and five ePosters accepted by the RSNA: presenting AI advancements for chest radiograph reporting efficiency and breast cancer risk assessment SEOUL, South Korea, Nov. 6, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer ...

2023-11-06 21:00 1218

Lunit to Present Seven AI-Powered Radiology Studies at RSNA 2023

First in the U.S! Palliative Care VR Educational Material by Jolly Good and Emergency Medicine Specialists

Jolly Good to hold VR Seminar at GSA 2023, Gerontological Society of America! TOKYO, Nov. 6, 2023 /PRNewswire/ -- Jolly Good US Inc. (Brookline, Massachusetts, USA CEO: Kensuke Joji), a developer of medical VR, is pleased to announce that it has developed the first "Palliative Care Communication ...

2023-11-06 21:00 1208

First in the U.S! Palliative Care VR Educational Material by Jolly Good and Emergency Medicine Specialists

Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications

Bispecific Antibody Candidate PM8002 demonstrated encouraging data at this year's ASCO Annual Meeting (abstract #2536 & #e13091) and ESMO Congress (abstract #1992P) BioNTech will hold exclusive licenses to develop and commercialize PM8002 globally excluding Greater China ZHUHAI, China, Nov. 6...

2023-11-06 20:00 1917

Dr.FORHAIR Announces U.S. In-Store Launch of Best Selling Hair Loss Shampoo

Global Scalp Care Brand to Launch Folligen Original Shampoo in 50 U.S. Costco Branches After Being Sold Online LOS ANGELES, Sept. 25, 2023 /PRNewswire/ -- Dr.FORHAIR, a global scalp care brand, has announced the first offline launch of its best selling Folligen Original Shampoo across 50 Costco ...

2023-11-06 16:48 711

Dr.FORHAIR Announces U.S. In-Store Launch of Best Selling Hair Loss Shampoo

David Beckham Signs Deal with TEMPUR to Promote The Benefits Of Sleep

LONDON, Nov. 6, 2023 /PRNewswire/ -- TEMPUR, a leading designer, manufacturer, distributor, and retailer of premium bedding products worldwide, has today announced the signing ofDavid Beckham as its newest brand ambassador.

2023-11-06 11:00 2758

David Beckham Signs Deal with TEMPUR to Promote The Benefits Of Sleep

The World's First "Recombinant Anthrax Vaccine": GC Biopharma applies for MFDS Approval

YONGIN, South Korea, Nov. 5, 2023 /PRNewswire/ -- GC Biopharma announced 1 Nov. 2023 that it has applied for the marketing approval of "GC1109", an anthrax vaccine jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA), to the Korean Ministry of Food and Drug...

2023-11-06 09:11 1225

PillWork's Upcoming Launch and its Landmark Partnership with Precision Nutrition Association

SEOUL, South Korea, Nov. 5, 2023 /PRNewswire/ -- With much anticipation surrounding its impending release, PillWork officially announces its launch scheduled for the end of 2023. An integral part of this excitement is the company's crucial alliance with the esteemed Precision Nutrition Associatio...

2023-11-06 09:00 1174

PillWork's Upcoming Launch and its Landmark Partnership with Precision Nutrition Association

Sanyou Bio Congratulates KangaBio on their IND Approval for Next-Generation IL-12 Prodrug Cancer Immunotherapy

SHANGHAI, Nov. 4, 2023 /PRNewswire/ -- On October 26, 2023, KangaBio announced that the U.S. FDA has granted official approval for their independent R&D clinical trial application (IND) for KGX101. KGX101 is a recombinant IL-12 Fc fusion protein designed for intravenous injection. The KGX101 clin...

2023-11-05 08:00 2193

The 2nd Boao International Conference on Real World Studies of Medical Products Held in Hainan

HAIKOU, China, Nov. 3, 2023 /PRNewswire/ -- On 31st Oct., the 2nd Boao International Conference on Real World Studies of Medical Products, held in Boao,Hainan, was attended by nearly 1,000 participants from domestic and international pharmaceutical regulatory agencies, academic societies, indust...

2023-11-03 12:10 546

The 2nd Boao International Conference on Real World Studies of Medical Products Held in Hainan

ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM

SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from three clinical studies of lisaft...

2023-11-03 09:15 517

ASH 2023 | For the Sixth Consecutive Year, Results from Multiple Clinical Studies of Olverembatinib Have Been Selected for Presentations, Including Two Oral Reports, at the 2023 ASH Annual Meeting

SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from multiple clinical studies of the ...

2023-11-03 09:10 476

PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.

* Melbourne ophthalmology company PolyActiva is developing a unique biodegradable ocular implant that provides 6 months of sustained drug delivery for patients with glaucoma, the second most common cause of irreversible blindness. * The interim Phase 2a results demonstrate a sustained >20% re...

2023-11-03 05:15 433

Complete Genomics and Basepair™ Announce Technology Integration Partnership

SAN JOSE, Calif. and NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Complete Genomics and Basepair, Inc today announced a technology integration partnership to accelerate the analysis and interpretation of genomic data generated by Complete Genomics' DNBSEQTM sequencing platforms*. The partnership gives ...

2023-11-02 21:00 650

Boryung Successfully Concludes 'Humans In Space Symposium' at 2023 ASCEND in Las Vegas

* HIS Symposium co-located with ASCEND, the world's event designed to accelerate the building of our sustainable off-world future, fromOctober 23 to 25. * Jay Kim, the Chairman and CEO of Boryung, invited as a speaker for ASCEND's opening and closing ceremonies and the panel discussion. * B...

2023-11-02 20:00 410

Boryung Successfully Concludes 'Humans In Space Symposium' at 2023 ASCEND in Las Vegas

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

* FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data from M-PLACE, a Phase 2 study led by I-Mab partner HI-Bio * I-Mab has full development and commercialization rights of felzartamab in Greater China for all indications, with Phase 3 multiple myelom...

2023-11-02 20:00 857

Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding inthe Simultaneous Presence of PD-1 & VEGF Cooperative Binding of Ivonescimab Enables Higher Avidity in the Tumor Microenvironmentwith Over 18 Fold Increased Binding Affinity to PD-1 in the Presence of VEGF in...

2023-11-02 20:00 458

Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis

SHENZHEN, China, Nov. 2, 2023 /PRNewswire/ -- On Oct. 31, 2023, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen" and with stock code 688321.SH) received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration ("NMPA") thro...

2023-11-02 15:58 1060

Precision, Effectiveness, and Intelligence: Explore the Latest Trend of Healthcare and Medical Equipment Industry at 134th Canton Fair

GUANGZHOU, China, Nov. 1, 2023 /PRNewswire/ -- As the public is paying increasing attention to health management, the 5-day onsite exhibition of Phase 3 of the 134th Canton Fair held from October 31st to November 4th will present nearly 600 quality exhibitors in medical and healthcare industries ...

2023-11-02 08:00 1503